NEPHROLOGY 2000; 5, 209–213
INTRODUCTION
Membranous nephropathy is a pathological diagnosis
found in 6% of all patients who have a renal biopsy to
evaluate proteinuria and up to 33% of adults who present
with the nephrotic syndrome.1 It remains a common
cause of end-stage renal disease throughout the world.
The aetiological agent is unknown in 70–80% of cases
and the disorder is termed idiopathic, whereas in the
other 20–30% a defined agent can be determined and
the disease is categorized as secondary (see Table 1).2,3
The depth of the search for secondary causes varies by
both the age of the patient and his geography. In Africa,
for instance, an infectious cause such as malaria is
common, and in Asia, hepatitis B is a frequent aetiologi-
cal agent. The issue of age relates to the association of
malignancy with membranous nephropathy.4 This asso-
ciation is stronger in the age group above 55 years. In
patients < 55 years, a search for an occult malignancy in
the absence of any signs or symptoms should be limited,
but investigations should probably include a chest
radiograph, a stool examination for occult blood, mam-
mography in women and, perhaps, a prostate-specific
antigen test in men. The surveillance should be main-
tained in the older patient as the time between
presentation of renal disease and malignancy is quite
variable and can be of a lengthy duration (years).
The following discussion will concentrate on the
treatment of the great majority of cases, i.e. the idio-
pathic membranous nephropathy category (IMGN). The
natural history of untreated IMGN has been documented
in several studies and must be known prior to consider-
ing therapy. Spontaneous remission occurs in 20–30% of
IMGN cases, progressive renal failure in 20–40%, and
the remaining patients retain mild to moderate pro-
teinuria even after 5–10 years of observation. A summary
of 11 studies demonstrated a 10-year survival rate of
between 65% and 85%, and a recent pooled analysis of
32 reports indicated a 60% renal survival at 15 years.5,6
Understanding the natural history is further complicated
by a spontaneous remitting and relapsing course in many
patients.7 Complete remission can be seen in as many
as 35% of the subjects of long-term (> 10 years) studies,
with up to 50% having at least one relapse. A com-
plete remission and a reduction in the relapse rate is
more common in female patients and those with per-
sistent subnephrotic-range proteinuria. In contrast,
the male gender, age > 50 years, high levels of protein-
uria (> 5 g/d), abnormal renal function at presentation
and tubular interstitial disease on biopsy have all been
associated with a poor prognosis.
PREDICTING OUTCOME
A method that accurately predicts outcome at an early
stage of the disease would substantially aid in the
management of the IMGN patient. A semi-quantitative
method of predicting outcome has been developed and
validated.8 It uses the clinical parameters of proteinuria
and creatinine clearance estimates over fixed periods of
time. In its simplest form, it demonstrated that the
overall accuracy of predicting outcome when proteinuria
values over 6-month time frames were persistently ≥ 4 g/d
was 71%, ≥ 6 g/d was 79% and ≥ 8 g/d was 84%. If the
Review
Management of membranous nephropathy
Daniel CATTRAN
General Division, Toronto, Ontario, Canada University Health Network, Toronto
SUMMARY: The Management of membranous nephropathy requires a recognition of its natural
history and an ability to predict those pationts with the worst prognosis. Treatment of those at risk of
progression with immunosuppressive drugs should be accompanied by additional conservative
risk reduction strategies such as dietary protein restriction, blood pressure reduction, angiotensin-
converting enzyme inhibitors and lipid-lowering agents. Anticoagulants should also be considered as
well as medications to reduce drug toxicity.
KEY WORDS: membranous nephropathy, treatment.
Correspondence: D Cattran, University Health Network, General
Division, CCRW3-884, College Street, Toronto, Ontario M5G,
Canada.
Accepted for publication 5 July 2000.
immune component of the disease, (ii) non-specific
therapy focused on reducing proteinuria and, secondar-
ily, slowing the progression to renal failure, (iii) treat-
ment of the secondary effects of the disease on other
systems, and (iv) treatment aimed at reducing the
complications of immune-modulating drugs.
Specific immunosuppression treatment
Low-risk patients
The prognosis of patients with these criteria is excellent.
In a series of over 300 cases from three distinct geo-
graphical regions followed for more than 5 years, only 5%
went on to develop chronic renal insufficiency.8 Strate-
gies to reduce protein excretion further and idealization
of blood pressure through the use of agents such as
angiotensin-converting enzyme inhibitors should be
utilized. As the percentage that progresses is not zero,
long-term follow-up should be maintained and include
regular measurements of blood pressure, renal function
and protein excretion. Immunosuppressive therapy is not
recommended and, in the majority of cases, treatment of
secondary effects of the disease is not required.
Medium-risk patients
Corticosteroids alone have been shown to be ineffective
in inducing remissions of nephrotic syndrome in all con-
trolled trials performed to date and in slowing progres-
sion in all but one trial.9,10 Although the follow-up
periods were limited to less than 4 years and the dose and
duration varied, the evidence indicates that these drugs
alone should not be used in the management of this type
of IMGN patient.
There is evidence of benefit when corticosteroids are
combined with a cytotoxic agent. In a series of random-
ized trials from Italy, a significant increase in both partial
and complete remissions in proteinuria and a reduc-
tion in the frequency of renal failure was observed.11,12
patient’s creatinine clearance was below normal at the
beginning of these time periods and/or deterioration of
renal function took place over the 6 months of observa-
tion, the accuracy was even higher. The advantages of
the algorithm are its reliance on very few factors, all of
which are standard measurements of renal function and
its dynamic nature, i.e. the ability to repeatedly calculate
the risk over the course of the patient’s disease. The
issues of age, gender, degree of sclerosis on biopsy and
hypertension are still important in the individual
patient, but do not add to the predictive capacity of this
model.
These observations on the natural history and our
ability to predict outcome must be the background upon
which current therapies are evaluated. This is particu-
larly true given the substantial risk associated with most
of our immune-modulating regimens. It therefore seems
appropriate to segregate the patients studied to date into
those that have a low risk and those that have a high risk
of progression and then evaluate the published trials of
different therapies based on their risk profile.
RISK OF PROGRESSION CATEGORIES
Low risk of progression patients have normal serum cre-
atinine and creatinine clearance values and proteinuria
< 3.5 g/d.
Medium-risk patients have normal or near normal
creatinine and creatinine clearance values and persistent
proteinuria over 6 months of between 3.5 and 6 g/d.
High-risk patients include those with moderate- to
high-grade proteinuria (≥ 6 g/d) persistent over 6 months
plus creatinine values either above normal or rising
during the observation period. Additional features in this
group may include hypertension and interstitial disease
and/or glomerular obsolescence on renal biopsy.
TREATMENT OPTIONS
Treatment can be considered in four broad categories:
(i) immunosuppressive therapy aimed at modulating the
210 NEPHROLOGY D Cattran
Table 1 Secondary causes of membranous nephropathy
Aetiology Examples
Neoplasms Carcinomas (especially solid organ tumours of the lung, colon, breast and kidney), leukaemia, lymphoma
(non-Hodgkin’s)
Infections Malaria, hepatitis B and C, secondary or congenital syphilis, leprosy
Drugs Penicillamine, gold
Immunological Systemic lupus erythematosus, mixed connective tissue disease, thyroiditis, dermatitis herpetiformis
Post renal transplant Recurrent disease, de novo membranous nephropathy
Miscellaneous Sickle cell anaemia
This list is illustrative of potential causes and is not meant to be exhaustive. Successful treatment of the associated disease or removal of the
offending agent in the secondary types have been shown to be accompanied by resolution of both the clinical and histological features.
Therapy consisted of 1 g of methylprednisolone i.v. on
the first 3 d of months 1, 3 and 5, followed by 27 days of
oral methylprednisolone at 0.4 mg/kg alternating in
months 2, 4 and 6 with chlorambucil at 0.2 mg/kg/d.
Utilizing this routine and following patients for up to
10 years, 40% of untreated patients reached end-stage
renal disease compared with only 8% of the treated
patients, and a non-nephrotic state was maintained
during only 22% of the total follow-up time compared
with 58% in the active drug group. When cyclopho-
sphamide was substituted for the chlorambucil using the
same study design a similar response was seen, although
the follow-up was limited to 3 years. In this latter study,
the relapse rate was substantial and occurred in approxi-
mately 30% of both groups within 2 years of treatment.
This therapeutic regime proved to be quite safe, with
only 10% of the patients stopping therapy owing to
adverse affects.
High-risk patients
The percentage of IMGN patients in this category is
small and very few have been the subject of randomized
controlled trials. In a subgroup analysis of patients with
initial renal insufficiency in one of the corticosteroid-
alone trials, no difference was seen in the rate of deteri-
oration over 4 years of follow-up. One small uncontrolled
trial using pulse methylprednisolone for 5 d did show
initial stabilization in 15 IMGN patients with renal
failure, but, at follow-up, two had died and five had pro-
ceeded to end-stage renal disease, suggesting the benefit
may be transient.13 Two small studies have used modifi-
cations of the Italian regimen in patients with IMGN
with progressive renal insufficiency. One series showed
approximately 50% of the 20 treated patients had an
improvement, but the adverse event rate was high, even
with an appropriate reduction in chlorambucil dosage.
Cyclophosphamide combined with pulse methylpred-
nisolone and oral prednisone has been compared with
alternate-day prednisone alone in a randomized trial in
such patients.14 There was no significant benefit observed
by the addition of the cytotoxic agent.
In early uncontrolled studies, cyclosporine was asso-
ciated with some benefit, but a high relapse rate, in this
type of IMGN patient. A recent randomized controlled
trial showed a significant reduction in proteinuria in the
eight treated patients compared with the eight untreated
patients that was sustained for up to 2 years in 50% of
cases.15 The rate of progression was substantially slowed,
as measured by an improvement in the slope of creati-
nine clearance of > 60% during treatment. This drug is
expensive and has nephrotoxic potential so monitoring
for this and other adverse events must be part of any
routine that includes this agent.16 Long-term oral
cyclophosphamide with and without prednisone has
been used in two smaller non-randomized trials. Both
found benefit, but the risks of prolonged cytotoxic
therapy, such as infertility, infection and malignancy, are
significant and have limited this approach.
Non-immunological treatment
Dietary protein restriction has not been shown to be
associated with a complete remission of the nephrotic
syndrome. However, most dietary protein restriction
trials have shown that maximum benefit accrues in those
patients with the heaviest proteinuria.17 Certainly many
IMGN patients would fulfil this criterion.
Blood pressure reduction does improve proteinuria,
and angiotensin-converting enzyme inhibitors have
been shown to reduce urine protein excretion in excess
of their anti-hypertensive effect in several studies of
patients with diabetic and non-diabetic glomerular dis-
eases.18,19 An additional benefit has also been demon-
strated in IMGN patients, but the studies have been
small, uncontrolled and with limited follow-up.20 The
mechanism for the anti-proteinuric effect is not fully
understood, but it does not appear to involve merely a
reduction in glomerular filtration rate.
Treatment of the secondary effects of the disease
Attention must be paid to the associated hyper-
lipidaemia and increased risk of thromboembolism in
patients with persistent heavy proteinuria and/or
impaired renal function. The group with the nephrotic
syndrome will have elevated serum cholesterol and
triglycerides values and normal or low levels of high-
density lipoproteins (HDL) and increased low-density
(LDL).21 This probably plays a central role in the
increased risk of cardiovascular disease in such patients.
Although no randomized trial has been carried out in
this specific group, HMG Co-A reductase inhibitors
have been shown to be safe and effective and many clin-
icians apply evidence from the non-renal disease litera-
ture to advocate their use in these patients.
Studies of the risk of thrombotic disease in IMGN
have shown a wide variation in prevalence, partly related
to the rigour of screening and partly to the detection
methods used.22 In a recent review, deep venous throm-
boses were reported in 11%, clinically significant pul-
monary emboli in 11% and renal vein thrombosis in 35%
of IMGN patients.23 Other studies have reported a lower
rate and a higher than average risk associated with long-
term anticoagulant therapy, perhaps related to the com-
monly associated hypoalbuminaemia state. No consensus
has emerged whether prophylactic anticoagulation
should be used, although if the former figures are correct
and the results are viewed in the light of data from
patients receiving anticoagulants in other populations,
the benefits would appear to outweigh the risks. The
Management of membranous nephropathy NEPHROLOGY 211
2) In the majority of cases, the patient’s renal function
should be monitored over a 6-month period utilizing
maximum conservative (non-immunosuppressive)
therapy and a risk of progression score established.
3) If persistent high-grade proteinuria and/or deteriora-
tion in renal function continues, despite maximum con-
servative therapy, introduce treatment for the secondary
effects of the disease, such as a lipid-lowering agent and
possibly anticoagulants.
4) The first choice of specific therapy for medium risk of
progression patients is the chlorambucil or cyclophos-
phamide/prednisone routine for 6 months.
5) Specific therapy for high-risk patients should be
either the modified chlorambucil/prednisone routine or
cyclosporin for 6–12 months.
6) Introduce risk reduction strategies, such as biphos-
phonates or other agents, when long-term corticosteroids
are used, and trimethoprim-sulphamethoxazole if long-
term immunosuppressive drugs are employed.
7) If both specific therapies fail and the clinical status
warrants further attempts at treatment, consider cyclo-
phosphamide alone for a maximum of 6–12 months.
REFERENCES
1. Haas M. Changing aetiologies of unexplained adult nephrotic syn-
drome: a comparison of renal biopsy findings from 1976–1979 and
1995–97. Am. J. Kidney. Dis. 1976; 30: 621–31.
2. Honkanen E, Tornroth T, Gronhagen-Riska C. Natural history,
majority of nephrologists today use this therapy as
primary prevention only in high-risk cases and reserve its
general use until after documentation of a thromboem-
bolic event.
Treatment prophylaxis
Several large studies in the renal transplant field and in
post-menopausal women have indicated that agents such
as biphosphonates reduce bone loss during long-term
use of corticosteroids. Utilization of such therapy in
the IMGN patient should be considered when the
course of therapy includes prolonged prednisone treat-
ment. Trimethoprim-sulphamethoxazole has reduced the
incidence of Pneumocystis carinii pneumonia (PCP) in
patients on prolonged immunosuppressive therapy in
both the transplant field and in certain autoimmune dis-
eases. Its use when IMGN patients are exposed to pro-
longed cytotoxic agents seems prudent.
MANAGEMENT PLAN
Figure 1 gives a graphic display of a treatment algorithm
for patients with IMGN. In addition, the following
general rules should be applied:
1) Establish whether the disease is primary or secondary
and take appropriate actions for known causes.
212 NEPHROLOGY D Cattran
Fig. 1 Guideline for the treatment of idiopathic membranous nephropathy. Patients may change from one category to another during
the course of follow-up. asupported by evidence from controlled trials; ACEi, angiotensin-converting enzyme-inhibiting drug; **intro-
duction of risk reduction strategies for both the disease and the therapy.
clinical course and morphological evolution of membranous
nephropathy. Nephrol. Dial. Transplant. 1992; 7: 35–41.
3. Hall CL, Jawad S, Harrison PR et al. Natural course of penicil-
lamine nephropathy: a long term study of 33 patients. Br. Med. J.
1988; 296: 1083–6.
4. Burstein DM, Korbet SM, Schwartz MM. Membranous glomeru-
lonephritis and malignancy. Am. J. Kidney. Dis. 1993; 22: 5–10.
5. Cattran DC, Pei Y, Greenwood C. Predicting progression in mem-
branous glomerulonephritis. Nephrol. Dial. Transplant. 1992; 7:
48–52.
6. Hogan SL, Muller KE, Jennette JC, Falk RJ. A review of thera-
peutic studies of idiopathic membranous glomerulopathy. Am. J.
Kidney. Dis. 1995; 25: 862–75.
7. Schieppati A, Mosconi L, Perna A et al. Prognosis of untreated
patients with idiopathic membranous nephropathy. N. Engl. J.
Med. 1993; 329: 85–9.
8. Cattran DC, Pei Y, Greenwood CM, Ponticelli C, Passerini P,
Honkanen E. Validation of a predictive model of idiopathic mem-
branous nephropathy: its clinical and research implications. Kidney
Int. 1997; 51: 901–7.
9. Cattran DC, Delmore T, Roscoe J et al. A randomized controlled
trial of prednisone in patients with idiopathic membranous
nephropathy. N. Engl. J. Med. 1989; 320: 210–5.
10. Cameron JS, Healy MJ, Adu D. The Medical Research Council
trial of short-term high-dose alternate day prednisolone in idio-
pathic membranous nephropathy with nephrotic syndrome in
adults. The MRC Glomerulonephritis Working Party. Q.J. Med.
1990; 74: 133–56.
11. Ponticelli C, Zucchelli P, Passerini P et al. A 10-year follow-up of
a randomized study with methylprednisolone and chlorambucil in
membranous nephropathy. Kidney Int. 1995; 48: 1600–4.
12. Ponticelli C, Altieri P, Scolari F et al. A randomized study com-
paring methylprednisolone plus chlorambucil versus methylpred-
nisolone plus cyclophosphamide in idiopathic membranous
nephropathy. J. Am. Soc. Nephrol. 1998; 9: 444–50.
13. Warwick GI, Geddes CG, Boulton-Jones JM. Prednisolone and
chlorambucil therapy for idiopathic membranous nephropathy
with progressive renal failure. Q.J. Med. 1994; 87: 223–9.
14. Falk RJ, Hogan SL, Muller KE, Jennette JC. Treatment of pro-
gressive membranous glomerulopathy. A randomized trial compar-
ing cyclophosphamide and corticosteroids with corticosteroids
alone. The Glomerular Disease Collaborative Network. Ann.
Intern. Med. 1992; 116: 438–45.
15. Cattran DC, Greenwood C, Ritchie S et al. A controlled trial of
cyclosporine in patients with progressive membranous nephropa-
thy. Canadian Glomerulonephritis Study Group. Kidney Int. 1995;
47: 1130–5.
16. Fritsche L, Budde K, Farber L et al. Treatment of membranous
glomerulopathy with cyclosporin A. how much patience is
required. Nephrol. Dial. Transplant. 1999; 14: 1036–7.
17. Klahr S, Levey AS, Beck GJ et al. The